Ward KW - Search Results

1

Enhancement of in vitro and in vivo microdialysis recovery of SB-265123 using Intralipid and Encapsin as perfusates.

Ward KW, Medina SJ, Portelli ST, Mahar Doan KM, Spengler MD, Ben MM, Lundberg D, Levy MA, Chen EP. Ward KW, et al. Biopharm Drug Dispos. 2003 Jan;24(1):17-25. doi: 10.1002/bdd.332. Biopharm Drug Dispos. 2003. PMID: 12516075

2

Pharmacokinetics of SB-247083, a potent and selective endothelin(A) receptor antagonist, in the rat, dog, and monkey.

Ward KW, Azzarano LM, Morgan JA, Gould MJ, Perng CY, Souder PR, Lundberg D, Smith BR. Ward KW, et al. Biopharm Drug Dispos. 2002 Nov;23(8):339-49. doi: 10.1002/bdd.331. Biopharm Drug Dispos. 2002. PMID: 12415574

3

Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics.

Ward KW, Proksch JW, Levy MA, Smith BR. Ward KW, et al. Drug Metab Dispos. 2001 Jan;29(1):82-8. Drug Metab Dispos. 2001. PMID: 11124234

4

Evaluation of the use of accelerated infusions for the determination of pharmacokinetic linearity.

Ward KW, Griffiths R, Levy MA, Smith BR. Ward KW, et al. J Pharmacol Exp Ther. 2000 May;293(2):468-79. J Pharmacol Exp Ther. 2000. PMID: 10773017

5

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man.

Ward KW, Proksch JW, Gorycki PD, Yu CP, Ho MY, Bush BD, Levy MA, Smith BR. Ward KW, et al. Xenobiotica. 2002 Mar;32(3):235-50. doi: 10.1080/00498250110100711. Xenobiotica. 2002. PMID: 11958562

6

Preclinical pharmacokinetics and interspecies scaling of a novel vitronectin receptor antagonist.

Ward KW, Azzarano LM, Bondinell WE, Cousins RD, Huffman WF, Jakas DR, Keenan RM, Ku TW, Lundberg D, Miller WH, Mumaw JA, Newlander KA, Pirhalla JL, Roethke TJ, Salyers KL, Souder PR, Stelman GJ, Smith BR. Ward KW, et al. Drug Metab Dispos. 1999 Nov;27(11):1232-41. Drug Metab Dispos. 1999. PMID: 10534306

7

SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.

Ward KW, Proksch JW, Azzarano LM, Salyers KL, McSurdy-Freed JE, Molnar TM, Levy MA, Smith BR. Ward KW, et al. Pharm Res. 2001 Sep;18(9):1336-44. doi: 10.1023/a:1013002414678. Pharm Res. 2001. PMID: 11683250

8

SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. I: preclinical pharmacokinetics.

Ward KW, Proksch JW, Salyers KL, Azzarano LM, Morgan JA, Roethke TJ, McSurdy-Freed JE, Levy MA, Smith BR. Ward KW, et al. Xenobiotica. 2002 Mar;32(3):221-33. doi: 10.1080/00498250110100720. Xenobiotica. 2002. PMID: 11958561 Clinical Trial.

9

Preclinical pharmacokinetics of SB-203580, a potent inhibitor of p38 mitogen-activated protein kinase.

Ward KW, Prokscht JW, Azzaranot LM, Mumawa JA, Roethke TJ, Stelman GJ, Walsh MJ, Zeigler KS, McSurdy-Freed JE, Kehlert JR, Chokshi J, Levy MA, Smith BR. Ward KW, et al. Xenobiotica. 2001 Nov;31(11):783-97. doi: 10.1080/00498250110065621. Xenobiotica. 2001. PMID: 11765141

10

Apparent absolute oral bioavailability in excess of 100% for a vitronectin receptor antagonist (SB-265123) in rat. I. Investigation of potential experimental and mechanistic explanations.

Ward KW, Azzarano LM, Evans CA, Smith BR. Ward KW, et al. Xenobiotica. 2004 Apr;34(4):353-66. doi: 10.1080/0049825042000205540. Xenobiotica. 2004. PMID: 15268980

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

113 results

Search Page

Filters